S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:ALEC

Alector (ALEC) Stock Price, News & Analysis

$5.09
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$4.95
$5.21
50-Day Range
$5.07
$7.41
52-Week Range
$3.66
$9.06
Volume
473,695 shs
Average Volume
557,557 shs
Market Capitalization
$487.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50

Alector MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
184.9% Upside
$14.50 Price Target
Short Interest
Bearish
8.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.53mentions of Alector in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$211,434 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.89) to ($2.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.70 out of 5 stars

Medical Sector

232nd out of 907 stocks

Biological Products, Except Diagnostic Industry

32nd out of 149 stocks

ALEC stock logo

About Alector Stock (NASDAQ:ALEC)

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

ALEC Stock Price History

ALEC Stock News Headlines

Alector, Inc. (NASDAQ:ALEC) Sees Large Growth in Short Interest
“More countries ditch the US dollar”
Since March 2018, China started purchasing oil in gold-backed yuan. By December 2022, Foreign Minister Wang Yi stated that Chinese-Arab relations experienced a "historic improvement." after arab nations ditched the dollar to trade with China. On June 6, 2023 China told its banks to slash interest rates on US dollars.
ALEC Jan 2025 7.500 call
ALEC Oct 2024 7.500 put
“More countries ditch the US dollar”
Since March 2018, China started purchasing oil in gold-backed yuan. By December 2022, Foreign Minister Wang Yi stated that Chinese-Arab relations experienced a "historic improvement." after arab nations ditched the dollar to trade with China. On June 6, 2023 China told its banks to slash interest rates on US dollars.
Alector to Participate in Upcoming Healthcare Conferences
TD Cowen Sticks to Their Buy Rating for Alector (ALEC)
Recap: Alector Q4 Earnings
Earnings Outlook For Alector
Here's what to expect from Alector's earnings
ALEC Mar 2024 7.500 call
Alector’s Promising Pipeline and Market Potential Affirm Buy Rating
GSK Feb 2024 42.000 put
See More Headlines
Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/21/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALEC
Fax
N/A
Employees
244
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$14.50
High Stock Price Target
$41.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+184.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-130,390,000.00
Net Margins
-134.34%
Pretax Margin
-128.97%

Debt

Sales & Book Value

Annual Sales
$97.06 million
Book Value
$1.41 per share

Miscellaneous

Free Float
82,344,000
Market Cap
$487.37 million
Optionable
Optionable
Beta
0.79

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Arnon Rosenthal Ph.D. (Age 68)
    Co-Founder, CEO & Director
    Comp: $1.02M
  • Dr. Sara Kenkare-Mitra Ph.D. (Age 56)
    President and Head of Research & Development
    Comp: $1.19M
  • Dr. Marc Grasso M.D. (Age 50)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $738.05k
  • Dr. Gary Romano M.D. (Age 62)
    Ph.D., Chief Medical Officer
    Comp: $602.98k
  • Mr. Peter Heutink Ph.D.
    Chief Scientific Officer
  • Katie Hogan
    Senior Director of Corporate Communication & Investor Relations
  • Ms. Danielle Pasqualone J.D.
    Ph.D., General Counsel
  • Ms. Clare Hunt M.B.A.
    Chief People Officer
  • Ms. Kristina Cutter M.P.H.
    Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
  • Ms. Virginia DeJesus-Rueff M.B.A.
    Chief of Staff & Head of Strategy

ALEC Stock Analysis - Frequently Asked Questions

Should I buy or sell Alector stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALEC shares.
View ALEC analyst ratings
or view top-rated stocks.

What is Alector's stock price target for 2024?

7 Wall Street research analysts have issued twelve-month price objectives for Alector's shares. Their ALEC share price targets range from $4.00 to $41.00. On average, they anticipate the company's stock price to reach $14.50 in the next year. This suggests a possible upside of 184.9% from the stock's current price.
View analysts price targets for ALEC
or view top-rated stocks among Wall Street analysts.

How have ALEC shares performed in 2024?

Alector's stock was trading at $7.98 at the start of the year. Since then, ALEC shares have decreased by 36.2% and is now trading at $5.09.
View the best growth stocks for 2024 here
.

Are investors shorting Alector?

Alector saw a increase in short interest in March. As of March 31st, there was short interest totaling 6,470,000 shares, an increase of 10.6% from the March 15th total of 5,850,000 shares. Based on an average daily trading volume, of 690,900 shares, the short-interest ratio is presently 9.4 days. Approximately 8.9% of the shares of the stock are short sold.
View Alector's Short Interest
.

When is Alector's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALEC earnings forecast
.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) posted its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.31. The company had revenue of $15.19 million for the quarter, compared to the consensus estimate of $8.35 million. Alector had a negative trailing twelve-month return on equity of 77.15% and a negative net margin of 134.34%.

What ETF holds Alector's stock?

iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio.

What guidance has Alector issued on next quarter's earnings?

Alector issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60.0 million-$70.0 million, compared to the consensus revenue estimate of $100.9 million.

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

When did Alector IPO?

Alector (ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Who are Alector's major shareholders?

Alector's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman.
View institutional ownership trends
.

How do I buy shares of Alector?

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Alector have any subsidiaries?
The following companies are subsidiares of Alector: Alector LLC.
Read More
This page (NASDAQ:ALEC) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners